What is new in esophageal injury (infection, drug-induced, caustic, stricture, perforation)?

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 372-379

  Pace, Fabio ^a   Antinori, Spinello ^a   Repici, Alessandro ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Caustic ingestion; Drug induced esophagitis; Esophagitis in HIV infection; Infectious esophagitis

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALLOPURINOL; ALUMINUM PHOSPHIDE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; BOTULINUM TOXIN; CASPOFUNGIN; CAUSTIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOXYCYCLINE; ETIDRONIC ACID; GAMMA INTERFERON; GANCICLOVIR; HOMEOPATHIC AGENT; IBUPROFEN; INTERLEUKIN 4; MICAFUNGIN; MITOMYCIN C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RISEDRONIC ACID; RITUXIMAB; VALGANCICLOVIR; VORICONAZOLE;

ACNE VULGARIS; ASPIRATION PNEUMONIA; BALLOON DILATATION; CHAGAS DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS ACHALASIA; ESOPHAGUS CANDIDIASIS; ESOPHAGUS INJURY; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GEOGRAPHIC DISTRIBUTION; GRAFT REJECTION; HEARTBURN; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY GRAFT REJECTION; LENGTH OF STAY; LOADING DRUG DOSE; NONHODGKIN LYMPHOMA; OROPHARYNX CANCER; OROPHARYNX CANDIDIASIS; PAIN; PHARYNX DISEASE; PREVALENCE; PROSTHESIS FAILURE; RESPIRATORY FAILURE; REVIEW; SYMPTOM; ULCERATIVE ESOPHAGITIS; VAGOTOMY;

BACTERIAL INFECTIONS; BURNS, CHEMICAL; CAUSTICS; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; ESOPHAGEAL PERFORATION; ESOPHAGEAL STENOSIS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; HUMANS; MALE; MYCOSES; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 68049107381     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832ad2e4     Document Type: Review

References (56)

1. Mocroft A, Oancea C, van Lunzen J, et al. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 2005; 100:1446-1454. (Pubitemid 41032346)
2. Raufman JP. Declining gastrointestinal opportunistic infections in HIVinfected persons: a triumph of science and a challenge for our HAARTs and minds. Am J Gastroenterol 2005; 100:1455-1458.
3. Battegay M, Fluckinger U, Hirschel B, Furrer HJ. Late presentation of HIV-infected individuals. Antivir Ther 2007; 12:841-851.
4. Zhou J, Paton NI, Ditangco R, on behalf of the TREAT Asia HIV Observational DataBase. AIDS-defining illness diagnosed with in 90 days after starting highly active antiretroviral therapy among patients from the TREAT Asia HIV observational database. Intern J STD AIDS 2007; 18:446-452.
5. Hanna DB, Gupta LS, Jones LE, et al. AIDS-defining opportunistic illnesses in the HAART era in New York City. AIDS Care 2007; 19:264-272.
6. Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22:2461-2469.
7. Borges MC, Baima Colares JK, Malta Lima D, Fonseca BAL. Advantages and pitfalls of the polymerase chain reaction in the diagnosis of esophageal ulcers in AIDS patients. Dig Dis Sci 2008. [Epub ahead of print]
8. Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48:304-309.
9. Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008; 59:361-379. A well written review summarizing the results obtained with novel antifungal drugs in different clinical conditions including Candida esophagitis.
10. Tong KB, Murtagh KN, Lau C, Seifeldin R. The impact of esophageal candidiasis on hospital charges and costs across patients subgroups. Curr Med Res Opin 2008; 24:167-174. (Pubitemid 351160250)
11. Ramos-Casals M, Cuadrado MJ, Alba P, et al. Acute viral infections in patients with systemic lupus erythematosus. Description of 23 cases and review of the literature. Medicine 2008; 87:311-318.
12. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21:628-632. (Pubitemid 47399427)
13. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19:621-628.
14. Trappe R, Pohl H, Forberger A, et al. Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection. Transpl Infect Dis 2007; 9:42-45. (Pubitemid 46257191)
15. Niola P, Battaglia E, Casabianca A, et al. A case of Chagas' disease. Dig Liver Dis 2008; 40:906-907.
16. Schumis GA. Epidemiology of Chagas disease in nonendemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007; 102 (Suppl 1): 75-85.
17. de Lima MA, Cabrine-Santos M, Tavares MG, et al. Interstitial cells of Caial in chagasis megaesophagus. Ann Diagn Pathol 2008; 12:271-274.
18. Ribeiro MB, Crema E, Rodrigues V Jr. Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease. Hum Immunol 2008; 69:484-489.
19. Herbella FAM, Aquino JLB, Stefani-Nakano S, et al. Treatment of achalasia: lessons learned with Chagas' disease. Dis Esophagus 2008; 21:461-467.
20. Facco M, Brun P, Baesso I, et al. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV-1 antigens. Am J Gastroenterol 2008; 103:1598-1609. An interesting and well done study showing the role of HSV-1 as immune trigger of the inflammatory response leading to the neuronal damage observed in patients with idiopathic achalasia.
21. Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons? Am J Gastroenterol 2008; 103:1610-1612.
22. Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999; 28:298-305.
23. Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol 2008; 24:496-501. The last year review on drug-induced, infectious and allergic esophageal injury. Comprehensive and useful.
24. Marshall J, Thabane M, James C. Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. Dig Dis Sci 2006; 51:864-868. (Pubitemid 44030804)
25. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999; 12:1152-1157.
26. Gómez V, Xiao SY. Alendronate-induce esophagitis in an elderly woman. Int J Clin Exp Pathol 2009; 2:200-203.
27. Tahan V, Sayrak H, Bayar N, et al. Doxycycline-induced ulceration mimicking esophageal cancer. Cases J 2008; 1:144.
28. Segelnick SL, Weinberg MA. Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review. J Am Dent Assoc 2008; 139:581-585.
29. Hillman L. Management strategies for Barrett's esophagus. J Gastroenterol Hepatol 2007; 22:771-772.
30. Sadeghi S, Bain CJ, Pandeya N, et al., Australian Cancer Study. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008; 17:1169-1178.
31. Ruszniewski P, Soufflet C, Barthelemy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther 2008; 28:1134-1139.
32. Cryer B, Spechler SJ. Effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on acid reflux in patients with gastroesophageal reflux disease (GERD). Gastroenterology 2000; 4 (Suppl 2):A862.
33. Singh NP, Rizk JG. Oesophageal perforation following ingestion of over-the-counter ibuprofen capsules. J Laryngol Otol 2008; 122:864-866.
34. Scheiman JM. Unmet needs in nonsteroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 2006; 66 (Suppl 1):15-21.
35. Darbari A, Tandon S, Chaudhary S, et al. Esophageal injuries due to aluminum phosphide tablet poisoning in India. Asian Cardiovasc Thorac Ann 2008; 16:298-300.
36. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graftversus-host disease-like changes. Am J Surg Pathol 2008; 329:1367-1372.
37. Corleto VD, D'Alonzo L, Zykaj E, et al. A case of oesophageal ulcer developed after taking homeopathic pill in a young woman. World J Gastroenterol 2007; 14:2132-2134. (Pubitemid 46795856)
38. Arévalo-Silva C, Eliashar R, Wohlgelernter J, et al. Ingestion of caustic substances: a 15-year experience. Laryngoscope 2006; 116:1422-1426. (Pubitemid 44181458)
39. Riffat F, Cheng A. Pediatric caustic ingestion: 50 consecutive cases and a review of the literature. Dis Esophagus 2009; 22:89-94.
40. Tohda G, Sugawa C, Gayer C, et al. Clinical evaluation of caustic injury in the gastrointestinal tract in 95 adult patients in an urban medical center. Surg Endosc 2008; 22:1119-1125.
41. Cheng HT, Cheng CL, Lin CH, et al. Caustic ingestion in adults: the role of endoscopic classification in predicting outcome. BMC Gastroenterol 2008; 8:31.
42. Bertelli P, Falchetti D, Giuliani S, et al., and the Caustic Ingestion Italian Study Group. Caustic ingestion in children: is endoscopy always indicated? The results of an Italian multicenter observational study. Gastrointest Endosc 2008; 68:434-439.
43. Salzman M, O'Malley RN. Updates on the evaluation and management of caustic exposures. Emerg Med Clin N Am 2007; 25:459-476. (Pubitemid 46669877)
44. PelclováD, Navrátil T. Do corticosteroids prevent oesophageal stricture after corrosive ingestion? Toxicol Rev 2005; 24:125-129.
45. Fulton JA, Hoffman RS. Steroids in second degree caustic burns of the esophagus: a systematic pooled analysis of fifty years of human data: 1956-2006. Clin Toxicol (Phila) 2007; 45:402-408.
46. Chirica M, de Chaisemartin C, Goasguen N, et al. Colopharyngoplasty for the treatment of severe pharyngoesophageal caustic injuries: an audit of 58 patients. Ann Surg 2007; 246:721-727. (Pubitemid 350035646)
47. Dua KS, Vleggaar FP, Santharam R, et al. Removable self-expanding plastic esophageal stent as a continuous, nonpermanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol 2008; 103:2988-2994. This is one of the largest prospective studies addressing the role of temporary selfexpanding plastic stents placement in the treatment of refractory benign strictures including those secondary to caustic ingestion.
48. Ragunath K. Refractory benign esophageal strictures: extending the role of expandable stents. Am J Gastroenterol 2008; 103:2995-2996.
49. Holmn AN, de la Mora Levy JG, Gostout CJ. Self-expanding plastic stents in treating benign esophageal conditions. Gastrointest Endosc 2008; 67:20-25. (Pubitemid 350266613)
50. Kochman ML, McClave SA, Boyce HW. The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc 2005; 62:474-475.
51. Ancona E, Guido E, Cutrone C, et al. A new endoscopic technique for suspension of esophageal prosthesis for refractory caustic esophageal strictures. Dis Esophagus 2008; 21:262-265. (Pubitemid 351593931)
52. Atabek C, Surer I, Demirbag S, et al. Increasing tendency in caustic esophageal burns and long-term polytetrafluorethylene stenting in severe cases: 10 years experience. J Pediatr Surg 2007; 42:636-640. (Pubitemid 46589522)
53. Daher P, Riachy E, Georges B, et al. Topical application of mitomycin C in the treatment of esophageal and tracheobronchial stricture: a report of 2 cases. J Pediatr Surg 2007; 42:E9-E11. (Pubitemid 47369357)
54. Rosseneu S, Afzal N, Yerushalmi B, et al. Topical application of mitomycin-C in oesophageal strictures. J Pediatr Gastroenterol Nutr 2007; 44:336-341. (Pubitemid 46673381)
55. Uhlen S, Fayoux P, Vachin F, et al. Mitomycin C: an alternative conservative treatment for refractory esophageal stricture in children? Endoscopy 2006; 38:404-407.
56. Heran MK, Baird R, Blair GK, Skarsgard ED. Topical mitomycin-C for recalcitrant esophageal strictures: a novel endoscopic/fluoroscopic technique for safe endoluminal delivery. J Pediatr Surg 2008; 43:815-818.